Management of Advanced Non–Small Cell Lung Cancer

Advances in non-small cell lung cancer that have helped lung oncologists make more informed treatment decisions with patients.

Challenges surrounding the screening of high-risk patients for lung cancer in the community.

Approaches that can help lung oncologists discuss symptoms and risk factors of non-small cell lung cancer with patients and their loved ones.

Drs. Charu Aggarwal and Hossein Borghaei comment on the importance of having predictive and prognostic biomarkers in non-small cell lung cancer and highlight their approaches to testing patients prior to initiating therapy.

Reactions to low rates of molecular testing for patients with non-small cell lung cancer in community settings.

What patients need to know about molecular testing and treatment decisions in non-small cell lung cancer.

The difference between tissue and liquid biopsies used in non-small cell lung cancer, and what patients should know about their results and treatment decision-making.

The rationale for waiting on results of molecular testing prior to initiating treatment for patients with non-small cell lung cancer.

The pros and cons of conducting PD-L1 testing in patients with non-small cell lung cancer.

Preferences for repeat biopsies upon progression in non-small cell lung cancer following frontline therapy with a targeted treatment approach.

Considerations for treating patients with non-small cell lung cancer with single-agent immunotherapy vs chemoimmunotherapy.

The significance of shared decision-making between patients and lung oncologists when considering a novel-based therapy as treatment for non-small cell lung cancer.

Strategies that can help various health care professionals best mitigate or manage side effects associated with newer treatments in non-small cell lung cancer, such as immunotherapy.

Preferences for rechallenging patients with non-small cell lung cancer with immunotherapy based on previous experiences in terms of treatment-related side effects.

Take-home messages from a discussion on the use of biomarker testing, and newer, novel-based strategies to treat patients with non-small cell lung cancer.